Saphnelo (anifrolumab-fnia) - AstraZeneca
Reduced Glucocorticoid Use in Patients With SLE Receiving Intravenous/Subcutaneous Anifrolumab Versus Placebo: Pooled Data From Phase 3 Clinical Trials (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2221; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; No abstract available 
Clinical • P3 data • Inflammatory Arthritis
https://eppro02.ativ.me/web/page.php?nav=false&page=Session&project=ACR26&id=3570225
 
Eric Morand, PhD, MBBS
 
Sep 8, 2026
 
Prev Next